Please use this identifier to cite or link to this item:
|Title:||Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE|
Low-molecular-weight heparin (LMWH)
|Citation:||Wong, J.E.-L. (2003-06). Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treatment Reviews 29 (SUPPL. 2) : 11-13. ScholarBank@NUS Repository.|
|Abstract:||The current practice of clinicians worldwide in the treatment of venous thromboembolism was assessed via responses to the FRONTLINE survey. Significant regional differences in practice were noted. Use of low-molecular-weight heparin was reported as the most common initial treatment for venous thromboembolism, although, in North America, unfractionated heparin was widely used to treat surgical cancer patients after a thrombotic episode. Oral anticoagulants were favoured for long-term treatment of venous thromboembolism, particularly in Western Europe and North America. Case study reports from the survey revealed that a substantial proportion of patients with cancer had been perceived to be at low risk of thrombosis, had consequently not received thromboprophylaxis and developed VTE. © 2003 Elsevier Science Ltd. All rights reserved.|
|Source Title:||Cancer Treatment Reviews|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 26, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.